Cargando…
Mutational signatures in squamous cell carcinoma of the lung
BACKGROUND: Tumor mutational burden (TMB) has been identified as one of the predictors for the response to anti-programmed cell death-1 (anti-PD-1) antibody therapy and reported to correlate with smoking history in lung adenocarcinoma. However, in squamous cell carcinoma of the lung, the association...
Autores principales: | Osoegawa, Atsushi, Takada, Kazuki, Okamoto, Tatsuro, Sato, Seijiro, Nagahashi, Masayuki, Tagawa, Tetsuzo, Tsuchida, Masanori, Oki, Eiji, Okuda, Shujiro, Wakai, Toshifumi, Mori, Masaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947495/ https://www.ncbi.nlm.nih.gov/pubmed/33717580 http://dx.doi.org/10.21037/jtd-20-2602 |
Ejemplares similares
-
Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
por: Sato, Seijiro, et al.
Publicado: (2018) -
Pulmonary metastasis presenting as a ground glass opacity-like lesion with a thin-walled cavity: A case report
por: Haro, Akira, et al.
Publicado: (2019) -
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma
por: Takada, Kazuki, et al.
Publicado: (2019) -
Next generation sequencing‐based gene panel tests for the management of solid tumors
por: Nagahashi, Masayuki, et al.
Publicado: (2018) -
(18)F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
por: Takada, Kazuki, et al.
Publicado: (2019)